Insider Buying: NextCure (NASDAQ:NXTC) Major Shareholder Purchases $1,443,750.50 in Stock

NextCure, Inc. (NASDAQ:NXTC) major shareholder Adar1 Capital Management, Llc bought 292,850 shares of the stock in a transaction on Thursday, July 30th. The stock was acquired at an average price of $4.93 per share, with a total value of $1,443,750.50. Following the completion of the acquisition, the insider owned 686,116 shares of the company’s stock, valued at $3,382,551.88. This represents a 74.47% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Adar1 Capital Management, Llc also recently made the following trade(s):

• On Friday, July 31st, Adar1 Capital Management, Llc purchased 36,303 shares of NextCure stock. The stock was bought at an average cost of $4.94 per share, with a total value of $179,336.82.
• On Wednesday, July 29th, Adar1 Capital Management, Llc bought 3,410 shares of NextCure stock. The stock was purchased at an average cost of $5.00 per share, with a total value of $17,050.00.
• On Tuesday, July 28th, Adar1 Capital Management, Llc acquired 6,400 shares of NextCure stock. The shares were purchased at an average price of $4.95 per share, with a total value of $31,680.00.
• On Monday, July 27th, Adar1 Capital Management, Llc purchased 7,798 shares of NextCure stock. The shares were acquired at an average price of $5.00 per share, with a total value of $38,990.00.

NextCure Trading Up 6.3%

Shares of NXTC traded up $0.26 on Monday, reaching $4.40. The company’s stock had a trading volume of 405,433 shares, compared to its average volume of 931,919. The firm has a fifty day moving average of $3.49 and a 200-day moving average of $8.65. The stock has a market capitalization of $15.89 million, a PE ratio of -0.26 and a beta of 1.42. NextCure, Inc. has a twelve month low of $1.55 and a twelve month high of $15.74.

NextCure (NASDAQ:NXTC) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($1.87) earnings per share for the quarter, beating the consensus estimate of ($2.10) by $0.23. As a group, equities analysts anticipate that NextCure, Inc. will post -7.89 EPS for the current fiscal year.

Institutional Trading of NextCure

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Marshall Wace LLP bought a new position in shares of NextCure in the fourth quarter valued at approximately $160,000. Millennium Management LLC bought a new stake in NextCure during the 4th quarter worth approximately $185,000. Geode Capital Management LLC lifted its stake in NextCure by 18.6% in the 4th quarter. Geode Capital Management LLC now owns 23,157 shares of the company’s stock worth $329,000 after purchasing an additional 3,636 shares in the last quarter. Renaissance Technologies LLC lifted its stake in NextCure by 18.7% in the 4th quarter. Renaissance Technologies LLC now owns 33,634 shares of the company’s stock worth $477,000 after purchasing an additional 5,300 shares in the last quarter. Finally, Boothbay Fund Management LLC purchased a new stake in shares of NextCure in the fourth quarter worth $988,000. 42.65% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on NXTC. Weiss Ratings downgraded NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, July 7th. Zacks Research upgraded NextCure from a “strong sell” rating to a “hold” rating in a research note on Thursday, June 11th. Wall Street Zen lowered NextCure from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. Finally, HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of NextCure in a research report on Wednesday, July 15th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $19.00.

NextCure Company Profile

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.